A Study of ATG-010 in Combination With Lenalidomide and Rituximab (R2) in Adults With DLBCL and iNHL
A Single-arm, Phase Ⅰ/Ⅱ Study Evaluating the Safety, Tolerability, and Preliminary Efficacy of ATG-010 in Combination with Lenalidomide and Rituximab (R2) in Adult Patients with Relapsed/Refractory DLBCL and iNHL Who are Ineligible for High-dose Chemotherapy (HDC) or Autologous Stem Cell Transplant (A SCT).
Diffuse Large B-cell Lymphoma|Indolent Non-Hodgkin Lymphoma
DRUG: ATG-010|DRUG: Lenalidomide|DRUG: Rituximab
DLT, The occurrence of severe toxicities during the first cycle of systemic cancer therapy, 28 days after administration|AE, Any adverse medical event that occurs after a patient or clinical trial subject receives a drug product, but is not necessarily related to the treatment., 28 days after administration
ORR, Percentage of subjects with PR, or CR, One year after last patient first dose|PFS, Duration of time from the first dose of study drug until progression or death due to any cause, One year after last patient first dose|DOR, Duration of time from first occurrence of CR or PR until the first date that disease, One year after last patient first dose|OS, Duration of time from the first dose of study drug until death due to any cause, One year after last patient first dose
A Single-arm, Phase Ⅰ/Ⅱ Study Evaluating the Safety, Tolerability, and Preliminary Efficacy of ATG-010 in Combination with Lenalidomide and Rituximab (R2) in Adult Patients with Relapsed/Refractory DLBCL and iNHL Who are Ineligible for High-dose Chemotherapy (HDC) or Autologous Stem Cell Transplant (ASCT).About 84 subjects are scheduled to be enrolled in the study,Maximum 24 (Dose Escalation Phase) and 60 (Dose Expansion Phase).